Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 31, Issue 11, 2004, Pages 2286-2289

  Haapasaari, Jarkko ^a   Kautiainen, Hannu J ^a   Isomäki, Heikki A ^a   Hakala, Markku ^a  

^a RHEUMATISM FOUNDATION HOSPITAL   (Finland)

Author keywords

Etanercept; Juvenile idiopathic arthritis; Refractory; Treatment costs

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERVIEW; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL RECORD; PARENT; PHYSIOTHERAPY; PRIORITY JOURNAL;

ADOLESCENT; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; FINLAND; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 7544232173     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schneider R, Passo MH. Juvenile rheumatoid arthritis. Rheum Dis Clin N Am 2002;28:503-30.
2. Savolainen HA, Isomäki HA. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol 1993;20:1201-36.
3. Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002;16:347-60.
4. Murray KJ, Lovell DJ. Advanced therapy for juvenile arthritis. Best Pract Res Clin Rheumatol 2002;16:361-78.
5. Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002;109:109-15.
6. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
7. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
8. Martini A. Etanercept improves active polyarticular juvenile rheumatoid arthritis. Clin Exp Rheumatol 2001;19:122-4.
9. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
10. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess 2002;6:1-43.
11. Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 2001;60:410-2.
12. Ten Cate RT, van Suijlekom-Smit LW, Brinkman DM, Bekkering WP, Jansen-van Wijngaarden CJ, Vossen JM. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology 2002;41:228-9.
13. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002;61:171-3.
14. Haapasaari J, Kautiainen H, Hakala M. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:867-70.
15. Ylijoki H. Re-evaluation on the factors determining the long-term clinical outcome of juvenile rheumatoid arthritis [Doctoral thesis]. Studies in Social Security and Health 31. Turku: Social Insurance Institution; 1998.
16. Heikkinen K, Hujanen T, Rusama H. Terveydenhuollon yksikkö kustannukset Suomessa vuonna 2000. Aiheita -monistesarja 23/2001. Helsinki: National Research and Development Centre for Welfare and Health.